Endocannabinoids are potential inhibitors of glioblastoma multiforme proliferation / 中西医结合学报

Globally, it is evident that glioblastoma multiforme (GBM) is an aggressive malignant cancer with a high mortality rate and no effective treatment options. Glioblastoma is classified as the stage-four progression of a glioma tumor, and its diagnosis results in a shortened life expectancy. Treatment options for GBM include chemotherapy, immunotherapy, surgical intervention, and conventional pharmacotherapy; however, at best, they extend the patient's life by a maximum of 5 years. GBMs are considered incurable due to their high recurrence rate, despite various aggressive therapeutic approaches which can have many serious adverse effects. Ceramides, classified as endocannabinoids, offer a promising novel therapeutic approach for GBM. Endocannabinoids may enhance the apoptosis of GBM cells but have no effect on normal healthy neural cells. Cannabinoids promote atypical protein kinase C, deactivate fatty acid amide hydrolase enzymes, and activate transient receptor potential vanilloid 1 (TRPV1) and TRPV2 to induce pro-apoptotic signaling pathways without increasing endogenous cannabinoids. In previous in vivo studies, endocannabinoids, chemically classified as amide formations of oleic and palmitic acids, have been shown to increase the pro-apoptotic activity of human cancer cells and inhibit cell migration and angiogenesis. This review focuses on the biological synthesis and pharmacology of endogenous cannabinoids for the enhancement of cancer cell apoptosis, which have potential as a novel therapy for GBM. Please cite this article as: Duzan A, Reinken D, McGomery TL, Ferencz N, Plummer JM, Basti MM. Endocannabinoids are potential inhibitors of glioblastoma multiforme proliferation. J Integr Med. 2023; 21(2): 120-128.

Cannabis medicinal: puntos críticos para su uso clínico / Medical cannabis: Critical points for clinical application

El cannabis se ha utilizado desde la antigüedad con fines recreativos y medicinales. Es una fuente muy rica de compuestos químicos, la mayoría denominados fitocannabinoides, que tienen una variedad de efectos fisiológicos, principalmente por su unión a receptores cannabinoides endógenos como el CB1 y CB2, entre otros. El cannabis tiene propiedades terapéuticas potenciales y sus preparaciones se han utilizado como remedios tradicionales para tratar el dolor y la emesis. Los cannabinoides sintéticos se utilizan clínicamente como analgésicos, antiespasmódico, antieméticos y estimulantes del apetito. La toxicidad significativa del cannabis es poco común en los adultos, sin embargo, puede tener múltiples efectos adversos agudos y crónicos. La calidad de la evidencia en este campo se ha visto limitada por la corta duración de los estudios, los reducidos tamaños de las muestras, la falta de grupos de control y la existencia de sesgos en la mayoría de los estudios revisados. En este contexto, son necesarios más estudios de mejor calidad metodológica para apoyar el uso seguro de esta terapia en otras enfermedades. La decisión de incorporar los cannabinoides como terapia en alguna de las condiciones descritas depende de la evidencia, el uso de terapias previas y el tipo de paciente.

Since ancient times cannabis has been used for recreational and medicinal purposes. It is a significant source of chemical compounds, most of them called phytocannabinoids. These compounds have several physiological effects and produce their effects primarily by binding to endogenous cannabinoid receptors such as CB1 and CB2, among others. Cannabis has potential therapeutic properties and its preparations have been used as traditional remedies to treat pain and emesis. Synthetic cannabinoids are used clinically as analgesics, antispastics, antiemetics, and appetite stimulants. Significant cannabis toxicity is rare in adults; however, it can produce countless acute and chronic side effects. The quality of the evidence in this field is limited by the short duration of the trials, poor sample sizes, lack of a control group, and the existence of bias in most of the reviewed studies. Therefore, a larger number of studies with better methodological quality is required to support the safe use of this therapy. The decision to include cannabinoids as a treatment for any of the conditions described will depend on the evidence, the use of previous therapies, and the type of patient.

O emprego da Cannabis medicinal no enfrentamento à doenças / The use of medicinal Cannabis in fighting diseases

A Cannabis possui como subespécie a Cannabis sativa. As plantas do gênero Cannabis possuem propriedades terapêuticas que são oriundas de compostos denominados canabinoides. O objetivo do presente artigo foi evidenciar como procede o uso terapêutico da Cannabis para enfrentamento das doenças. Realizou-se revisão narrativa da literatura com busca nas bases de dados: PubMED, Google Acadêmico com levantamento de artigos que tratavam acerca do uso da Cannabis medicinal para o tratamento de algumas doenças. Canabinoides correlacionam-se a receptores do nosso corpo, influindo nos mecanismos que regulam o organismo. Cannabis possibilita abordar e intervir em determinadas patologias presentes nos pacientes advindo de possuir ações benéficas anticonvulsivantes, anti-inflamatórias, analgésicas, ansiolíticas, antipsicóticas e antitumorais. Em nosso corpo existem os canabinoides ou endocanabinoides, que são similares aos canabinoides naturais ou fitocanabinoides estruturados na Cannabis. O canabidiol e o tetra-hidrocarbinol constituem canabinoides provenientes da Cannabis que podem tecer relação com os canabinoides configurados por nosso próprio corpo. O sistema de endocanabinoides possibilitou averiguar-se acerca do emprego do canabidiol para tratamento de patologias, como: Doença de Parkinson, Autismo e Epilepsia. Concluiu-se que o emprego terapêutico da Cannabis medicinal pode representar recurso que será válido para resolução do problema de saúde, podendo propiciar melhores condições e qualidade de vida aos pacientes portadores de determinadas patologias em que essa droga pode ser utilizada para tratamento.

Cannabis has Cannabis sativa as a subspecies. Cannabis plants have therapeutic properties that come from compounds called cannabinoids. The aim of this article was to show how the therapeutic use of Cannabis to cope with diseases proceeds. A narrative review of the literature was carried out with a search in the following databases: PubMED, Google Scholar with a survey of articles that dealt with the use of medicinal Cannabis for the treatment of some diseases. Cannabinoids correlate to our body's receptors, influencing the mechanisms that regulate the body. Cannabis makes it possible to address and intervene in certain pathologies present in patients arising from having beneficial anticonvulsant, anti-inflammatory, analgesic, anxiolytic, antipsychotic and antitumor actions. In our body there are cannabinoids or endocannabinoids, which are similar to natural cannabinoids or phytocannabinoids structured in Cannabis. Cannabidiol and Tetrahydrocannabinol are cannabinoids derived from Cannabis that can be related to cannabinoids configured by our own body. The endocannabinoid system made it possible to investigate the use of cannabidiol for the treatment of pathologies, such as: Parkinson's Disease, Autism and Epilepsy. It was concluded that the therapeutic use of medicinal Cannabis can represent a resource that will be valid for solving the health problem, providing better conditions and quality of life for patients with certain pathologies in which this drug can be used for treatment.

Medical cannabis and cannabidiol: A new harvest for Malawi

In February 2020 parliament passed the Cannabis Regulation Bill (2020) which regulates the cultivation and production of industrial hemp and medical cannabis. The country will only fully benefit from this development if the medical and scientific community can take the lead in enabling the country to exploit the plant's potential to help address some of our economic and public health challenges. This special communication provides some basic information on cannabis and discusses its history and medical uses. Cannabidiol (CBD) has emerged as one of the most important cannabis-derived phytochemicals and has formed the basis for the growth of the medical cannabis industry. The scientific data on the mechanisms of the effects of CBD on the human neuroendocrine-immune network is reviewed and the first effective cannabis-based FDA-approved treatment for epilepsy discussed. Some clinical research that is being done on the antipsychotic and neuroprotective properties of CBD is also reviewed. A case is made for the potential of CBD as a neuroprotective adjunctive therapy for the prevention of neuropsychological sequelae associated with complicated malaria. The safety profile of CBD is reviewed and finally, the potential importance of the re-medicalization of cannabis-based therapies for the broader field of phytomedicine is pointed out

Función de la impulsividad en el trastorno por consumo de sustancias / Impulsivity`s role in substance use disorder

Resumen La proporción de usuarios de una sustancia de abuso que desarrolla problemas con su consumo (abuso o dependencia) representa solo una parte de esta población. En México, el 63.8 % de la población consume alcohol, y de ellos, el 15 % desarrolla algún trastorno por consumo de alcohol (TCA). Se ha observado una relación causal entre el trastorno por consumo de sustancias (TCS) y la falta de autocontrol. Es decir, satisfacer necesidades de manera impulsiva, v. gr., consumir una droga sin evaluar las consecuencias. La corteza prefrontal (CPF) es el principal sustrato neuroanatómico del autocontrol y característicamente la CPF alcanza la madurez alrededor de los 30 años, sugieriendo que el autocontrol se alcanza despues de esta edad. Se ha propuesto que todos los grupos etarios que no han consolidado el uso del autocontrol son vulnerables al TCS. Similarmente ocurre con aquellos sujetos que por algún trastorno psiquiátrico tienen como característica una limitada función prefrontal. La CPF coordina una red subcortical cuya interacción depende de distintos sistemas de neurotransmisión, entre ellos, endocanabinoides. En este trabajo se revisó la función de la CPF y del sistema de endocanabinoides (sECB) y su relación con la vulnerabilidad a la adicción y otros trastornos psiquiátricos.

Abstract The proportion of users of a substance of abuse who develop problems with its use (abuse or dependence) represents only a part of this population. In Mexico, 63.8% of the population consumes alcohol and only 15% of them develop an alcohol use disorder (AUD). A causal relation has been observed between substance use disorder (SUD) and the lack of self-control. Which means, satisfying needs in an impulsive way, v.gr. using a drug, without considering the consequences. The prefrontal cortex (PFC) is the main neuroanatomical substrate of self-control and characteristically reaches maturity around the age of 30, suggesting that self-control is reached after this age. We suggest that all age groups that have not consolidated the use of self-control are vulnerable to SUD. The same occurs with those who, due to a psychiatric disorder, have the characteristic of a limited prefrontal function. The PFC coordinates a subcortical network whose interaction depends on different neurotransmission systems among them, the endocannabinoids system (ECBs). In this work we will review the function of the PFC, the ECBs and its relationship with vulnerability to addiction and other psychiatric disorders.

Cannabinoids in Neurology - Position paper from Scientific Departments from Brazilian Academy of Neurology / Canabinoides em Neurologia - Artigo de posicionamento dos Departamentos Científicos da Academia Brasileira de Neurologia

ABSTRACT Cannabinoids comprehend endocannabinoids, phytocannabinoids, and synthetic cannabinoids, with actions both in the central and peripherical nervous systems. A considerable amount of publications have been made in recent years, although cannabis has been known for over a thousand years. Scientific Departments from the Brazilian Academy of Neurology described evidence for medical use in their areas. Literature is constantly changing, and possible new evidence can emerge in the next days or months. Prescription of these substances must be discussed with patients and their families, with knowledge about adverse events and their efficacy.

RESUMO Os canabinoides compreendem os endocanabinoides, fitocanabinoides e os canabinoides sintéticos e desempenham ações no sistema nervoso central e periférico. Uma quantidade enorme de publicações tem sido lançada nos últimos anos, embora a cannabis seja conhecida por milênios. Os Departamentos Científicos da Academia Brasileira de Neurologia descreveram as evidências do uso médico em suas áreas. A literatura está em constantes mudanças e possíveis novas evidências podem surgir nos próximos dias ou meses. A prescrição dessas substâncias deve ser discutida com os pacientes e suas famílias, com conhecimento sobre eventos adversos e sua eficácia.

Cannabinoids for major neurocognitive disorder: case report and literature review / Uso de cannabinoides en trastorno neurocognitivo mayor: reporte de un caso y revisión de la literatura

ABSTRACT Introduction: Major neurocognitive disorder (MNCD) affects millions of people worldwide. However, the pharmacological options for its management are limited, ineffective and frequently associated with severe adverse reactions. Case report: An 85-year-old man with history of multiple chronic brain injuries (alcohol-use disorder, haemorrhagic stroke, brain trauma, chronic use of benzodiazepines) developed an MNCD, reaching 7 points on the Reisberg Global Deterioration Scale. He had minimal response to antidepressants, antipsychotics and anticholinergic medications. After the use of mother tincture of Indian hemp (cannabis), a significant improvement was found in his cognitive function, ability to carry out activities of daily living and independence. Discussion: The endocannabinoid system seems to be implicated in age-related cognitive decline. In addition, the evidence derived from in-vitro and animal models suggest that this system could play an important role in the management of MNCD of different causes. Conclusions: Cannabinoid treatment for MNCD emerges as a promising therapeutic approach that may benefit a growing number of patients who do not have other treatment options. It is therefore necessary to encourage more research efforts that will help to remove political and scientific barriers to its clinical use.

RESUMEN Introducción: El trastorno neurocognitivo mayor (TNM) afecta a millones de personas a nivel mundial. Sin embargo, las opciones farmacológicas para su manejo son limitadas, poco efectivas y se asocian a importantes reacciones adversas. Caso clínico: Se presenta el caso clínico de un hombre de 85 años, con antecedente de múltiples lesiones cerebrales crónicas (abuso de alcohol, enfermedad cerebrovascular, traumatismo cerebral, uso crónico de benzodiacepinas), quien desarrolló un TNM clasificado con 7 puntos en la Reisberg Global Deterioration Scale. Tuvo poca respuesta al manejo con antidepresivos, antipsicóticos y anticolinérgicos. Tras el uso de tintura madre de cáüamo índico (cannabis), se evidenció una mejoría en la función cognitiva, la capacidad de cuidado para las actividades de la vida diaria y la independencia. Discusión: El sistema endocanabinoide parece estar relacionado con los procesos de deterioro cognitivo asociados con la edad. Además, la evidencia derivada de modelos in vitro y animales sugiere que podría tener un papel importante en el manejo del TNM de diferentes etiologías. Conclusiones: El uso de cannabinoides en el TNM se presenta como una pista terapéutica prometedora. Por lo tanto, es necesario promover procesos de investigación que contribuyan a eliminar las barreras políticas y científicas para su uso clínico, beneficiando a un número creciente de pacientes que no poseen opciones terapéuticas eficaces.

Cannabis and the exocannabinoid and endocannabinoid systems. Their use and controversies

Cannabis (marijuana) is one of the most consumed psychoactive substances in the world. The term marijuana is of Mexican origin. The primary cannabinoids that have been studied to date include cannabidiol and delta-9-tetrahydrocannabinol, which is responsible for most cannabis physical and psychotropic effects. Recently, the endocannabinoid system was discovered, which is made up of receptors, ligands and enzymes that are widely expressed in the brain and its periphery, where they act to maintain balance in several homeostatic processes. Exogenous cannabinoids or naturally-occurring phytocannabinoids interact with the endocannabinoid system. Marijuana must be processed in a laboratory to extract tetrahydrocannabinol and leave cannabidiol, which is the product that can be marketed. Some studies suggest cannabidiol has great potential for therapeutic use as an agent with antiepileptic, analgesic, anxiolytic, antipsychotic, anti-inflammatory and neuroprotective properties; however, the findings on cannabinoids efficacy and cannabis-based medications tolerability-safety for some conditions are inconsistent. More scientific evidence is required in order to generate recommendations on the use of medicinal cannabis.

The Psychiatric Effects of Cannabis / 생물치료정신의학

With the recent legalization of recreational cannabis in Canada and 11 states of the U.S., the interest surrounding cannabis use is increasing. However, many people and even clinicians in Korea do not have exact knowledge about the psychiatric consequences of cannabis use. In this narrative review, the characteristics of cannabis, the endocannabinoid system, and the psychiatric consequences of cannabis use were provided. Cannabis contains more than 80 cannabinoids in the native plant. Psychotropic properties of Δ-9-tetrahydrocannabinol and cannabidiol are most well studied. The two main receptors are cannabinoid-1 receptor and cannabinoid-2 receptor. Several endocannabinoids, such as anandamide and 2-arachidonoylglycerol, act on the receptors as the endogenous ligands. Cannabis influences mood, cognitive functions, and psychomotor functions in acute phase responses, increasing the odds ratio for motor vehicle crashes. Long-term cannabis use is associated with various psychotic outcomes, including the development of schizophrenia, although there is interindividual variability. Cannabis adversely influences learning, memory, and attention. More frequent, persistent, and earlier onset cannabis use is associated with greater cognitive impairment. The chronic cognitive effects of cannabis are complex and controversial. Cannabis has addictive potential, and cannabis use disorder is common. Clinicians should have evidence-based knowledge about the consequences of cannabis use and communicate accurate information about cannabis use and its associated risks to the public.

The role of the CNR1 gene in schizophrenia: a systematic review including unpublished data

Objective: Schizophrenia is a multifactorial disorder. It is known that a combination of extensive multiple common alleles may be involved in its etiology, each contributing with a small to moderate effect, and, possibly, some rare alleles with a much larger effect size. We aimed to perform a systematic review of association studies between schizophrenia (and its subphenotypes) and polymorphisms in the CNR1 gene, which encodes cannabinoid receptors classically implicated in schizophrenia pathophysiology, as well as to present unpublished results of an association study in a Brazilian population. Methods: Two reviewers independently searched for eligible studies and extracted outcome data using a structured form. Papers were retrieved from PubMed and ISI Web of Knowledge using the search term schizophrenia in combination with CNR1 or CB1 or cannabinoid receptor. Twenty-four articles met our inclusion criteria. We additionally present data from a study of our own comparing 182 patients with schizophrenia and 244 healthy controls. Results: No consistent evidence is demonstrated. Conclusion: Some seemingly positive association studies stress the need for further investigations of the possible role of endocannabinoid genetics in schizophrenia.

Breve reseña sobre la farmacología de los cannabinoides / Brief review on the pharmacology of cannabinoids

Intensa resulta la controversia entre los que promueven el uso de los cannabinoides con fines terapéuticos y quienes consideran que es temprana aún la introducción de estos en la clínica, por sus efectos deletéreos para la salud humana en las diferentes etapas y condicionales del desarrollo biológico. Paralelamente se debate, entre las autoridades encargadas de velar por la salud de sus conciudadanos, la polémica de legalizar o no el consumo de la Cannabis sativa en cualquiera de sus formas y derivados naturales. Ambas polémicas han fundamentado el estudio de todas las formas de presentación y consumo de esta planta, así como de sus derivados sintéticos dados sus efectos sobre la salud de enfermos y sanos. En esta breve reseña se exponen aspectos relevantes de su farmacología, debido al interés y enorme caudal de información generado por un sinnúmero de investigadores dedicados al estudio de dicha planta y sus derivados

The controversy among those that promote the use of cannabinoids with therapeutic aims is intense and who consider that it is still early for their introduction in the clinic, due to their lethal effects for the human health in the different stages and conditionals of the biological development. In parallel it is debated, among the authorities in charge of looking after the health of their fellow citizens, the polemic of legalizing or not the consumption of the Cannabis sativa in any of their forms and natural derived. Both polemics have based the study of all the forms of presentation and consumption of this herb, as well as of its synthetic derived due to their effects on the health of sick and healthy people. In this brief review outstanding aspects of their pharmacology are exposed, due to the interest and enormous flow of information generated by a large number of investigators dedicated to the study of this herb and its derived elements

Progress in study on endocannabinoids and cannabinoid receptors in the treatment for neuropathic pain / 中南大学学报(医学版)

Endocannabinoids and cannabinoid receptors are expressed in various central pain modulation regions. They maintain in dynamic changes in the expression level and distribution under different pathological and physiological conditions. These changes possess advantage as well as disadvantage. Exogenous administration of endocannabinoids exerts analgesic effect in different pain models, which is mainly mediated by the cannabinoid CB1 and CB2 receptors. Inhibition of enzymes for degrading endocannabinoids in different pain models also shows analgesic effect due to the increased local levels of endocannabinoids.

Convenção-Quadro para o Controle do Tabaco: adesão e implantação na América Latina / WHO Framework Convention on Tobacco Control: adherence and establishment in Latin America

OBJETIVO:Traçar o panorama de adesão mundial à Convenção-Quadro para o Controle do Tabaco (CQCT) e descrever a implantação das medidas preconizadas pela CQCT em países latino-americanos. MÉTODOS: Este estudo descritivo baseou-se em análise de dados secundários para determinar o status de adesão, no ano de 2015, dos países das seis regiões definidas pela Organização Mundial da Saúde (OMS) à CQCT. Depois disso, realizou-se um mapeamento da implantação, até o ano de 2012, das medidas preconizadas pela CQCT no total de Estados Partes e particularmente em 12 Estados Partes latino-americanos. Finalmente, Brasil, Chile, Colômbia, México e Venezuela foram avaliados quanto ao grau de implantação da CQCT (incipiente, intermediária e avançada). Foram consideradas neste passo medidas englobadas por quatro eixos - redução da demanda por tabaco, redução da oferta de tabaco, redução dos danos ao ambiente e à saúde das pessoas causados pelo tabaco e apoio ao abandono do tabaco. RESULTADOS: Até agosto de 2015, 180 países haviam ingressado no rol de Estados Partes da CQCT. Considerando os 126 países que enviaram relatórios de progresso global da implantação no ciclo de 2012, as medidas mais prevalentes adotadas referiam-se à proteção contra a exposição à fumaça do tabaco (83,0% para o total de países e 100% para o conjunto de países latinoamericanos). Entre os cinco países selecionados para análise detalhada, as medidas destinadas à redução da demanda e da oferta do tabaco foram as mais frequentes. As medidas relacionadas à redução de danos ao ambiente foram raras. Brasil e México apresentaram a situação mais avançada de implantação entre os países estudados. CONCLUSÕES: A América Latina apresentou uma alta proporção de Estados Partes que implantaram as medidas preconizadas pela CQCT. A heterogeneidade da situação de implantação nos cinco países selecionados sugere que as políticas de controle de tabaco são condicionadas por particularidades nacionais.

OBJECTIVE: To draw an overview of the adherence of countries around the world to the World Health Organization Framework Convention on Tobacco Control (WHO FCTC) and to describe the establishment of WHO FCTC recommended measures in Latin American countries. METHODS: This descriptive study was based on analysis of documents and secondary data to determine the status of countries from the six WHO regions regarding adherence to the FCTC. After that, the establishment of recommended measures until the year 2012 was mapped in all States Parties and particularly in 12 Latin American States Parties. Finally, the degree to which FCTC measures had been established in Brazil, Chile, Colombia, Mexico, and Venezuela was assessed (incipient, intermediate, or advanced). This step took into consideration the measures covered by four domains - reduction in the demand for tobacco, reduction in the offer of tobacco, reduction in damage to the environment and to the health of people caused by tobacco, and support for quitting the use of tobacco. RESULTS: Until August 2015, 180 countries had joined as States Parties to the FCTC. Considering the 126 countries that submitted global progress reports in the 2012 cycle, the most prevalent measures adopted referred to the protection against exposure to tobacco smoke (83.0% for all countries and 100% for the group of Latin American countries). Among the five countries selected for detailed analysis, the measures referring to the reduction of demand and offer of tobacco were the most frequent. Measures focused on reducing environmental damage were rare. Brazil and Mexico had the most advanced FCTC status among the studied countries. CONCLUSIONS: Latin America presented a high proportion of States Parties with established FCTC recommended measures. The heterogeneity of the FCTC status in the five selected countries suggests that the implementation of tobacco control policies depends on specific aspects of each country.

Papel da Lipoxina A4 na fisiologia do sistema nervoso central e no dano cognitivo associado à neuroinflamação / Lipoxin A4 paper of the central nervous system physiology and cognitive impairment associated with neuroinflammation

O papel da lipoxina A4 (LXA4) no sistema imunológico é bem estudado, mas o papeldessa molécula na fisiologia do sistema nervoso central (SNC) só foi abordado recentemente.Como um modulador alostérico positivo, a LXA4 produz efeitos canabimiméticos e pode, dessaforma, estar envolvida em vßrios aspectos de funções fisiológicas reguladas pelo sistemaendocanabinóide (eCB). Nós investigamos essa hipótese analisando o comportamento decamundongos knockout (5-LO-/-) para a enzima 5-lipoxigenase (5-LO), que participa da síntesede LXA4. Ansiedade, consumo de ßgua e alimento, locomoção, nocicepção e memórias aversivassão comportamentos reconhecidos como sob controle do sistema eCB e foram avaliados nesteestudo. Nenhuma alteração foi observada no comportamento de 5-LO-/-em relação ao consumode ßgua e alimento e locomoção no teste de campo aberto. No entanto, o tratamento com LXA4produziu efeito ansiolítico no labirinto em cruz elevada. Além disso, inibição farmacológica da 5-LO demonstrou um efeito ansiogênico em animais idosos, mas não em adultos jovens, indicandoque a LXA4 endógena exerce um efeito regulatório sobre ansiedade de forma idade-dependente.Os animais 5-LO-/-apresentaram um aumento na sensibilidade e redução na tolerância à dor noteste de sensibilidade ao choque. Ainda, uma disfunção em memória de curto prazo e extinção dememória no teste de esquiva inibitória foi observada nos animais 5-LO-/-, indicando que a LXA4pode agir na facilitação do aprendizado...

The role of lipoxin A4 (LXA4) in the immune system is well studied, however the part thismolecule plays in central nervous system (CNS) physiology has only recently been addressed.LXA4, as a CB1 allosteric enhancer, has a cannabimimetic effect and may therefore be involvedin various aspects of endocannabinoid system (eCB) physiological functions. We investigatedthis reasoning by analyzing the behavior of 5-lipoxygenase (5-LO) knockout mice (5-LO-/-).Anxiety-like behavior, appetitive behavior, locomotion, nociception and learning and memory areall known to be under control of the eCB system and were assessed in this study. No alterationwas observed in the behavior of 5-LO knockout mice regarding appetitive behavior, measured byfood and water intake, or locomotion in the open field test. However, treatment with LXA4produced an anxiolytic-like effect on the elevated plus maze. Further, pharmacological inhibitionof 5-LO showed an anxiogenic-like effect in aged, but not adult mice, indicating that endogenousLXA4 has an age-dependent effect on the modulation of anxiety-like behavior. 5-LO-/- micepresented an increase in pain sensitivity and a decrease in pain tolerance in the foot shocksensitivity test. Interestingly, the animals also presented impairment in short-term memory andextinction learning in the step-down inhibitory avoidance task, pointing out that LXA4 may act inthe facilitation of fear learning. These data are of great importance to the possible use of LXA4 astreatment to neuroinflammation induced cognitive impairment.The study of sepsis reveals that an inflammatory stimulus can induce the exacerbatedproduction of pro-inflammatory cytokines in the CNS, which causes neuroinflammation andcognitive impairment...

A Cannabinoid Receptor Agonist N-Arachidonoyl Dopamine Inhibits Adipocyte Differentiation in Human Mesenchymal Stem Cells

Endocannabinoids can affect multiple cellular targets, such as cannabinoid (CB) receptors, transient receptor potential cation channel, subfamily V, member 1 (TRPV1) and peroxisome proliferator-activated receptor gamma (PPARgamma). The stimuli to induce adipocyte differentiation in hBM-MSCs increase the gene transcription of the CB1 receptor, TRPV1 and PPARgamma. In this study, the effects of three endocannabinoids, N-arachidonoyl ethanolamine (AEA), N-arachidonoyl dopamine (NADA) and 2-arachidonoyl glycerol (2-AG), on adipogenesis in hBM-MSCs were evaluated. The adipocyte differentiation was promoted by AEA whereas inhibited by NADA. No change was observed by the treatment of non-cytotoxic concentrations of 2-AG. The difference between AEA and NADA in the regulation of adipogenesis is associated with their effects on PPARgamma transactivation. AEA can directly activate PPARgamma. The effect of AEA on PPARgamma in hBM-MSCs may prevail over that on the CB1 receptor mediated signal transduction, giving rise to the AEA-induced promotion of adipogenesis. In contrast, NADA had no effect on the PPARgamma activity in the PPARgamma transactivation assay. The inhibitory effect of NADA on adipogenesis in hBM-MSCs was reversed not by capsazepine, a TRPV1 antagonist, but by rimonabant, a CB1 antagonist/inverse agonist. Rimonabant by itself promoted adipogenesis in hBM-MSCs, which may be interpreted as the result of the inverse agonism of the CB1 receptor. This result suggests that the constantly active CB1 receptor may contribute to suppress the adipocyte differentiation of hBM-MSCs. Therefore, the selective CB1 agonists that are unable to affect cellular PPARgamma activity inhibit adipogenesis in hBM-MSCs.

Sistema endocanabinoide y desarrollo de esteatosis hepática / A role for the endocannabinoid system in hepatic steatosis

The endocannabinoid system (SEC) is an important modulator of several metabolic functions. This system is composed by cannabinoid receptors type 1 and 2 (RCB1 and RCB2), their endogenous ligands, known as endocannabinoids, and the enzymes involved in their synthesis and degradation. A deregulated SEC originates metabolic alterations in several tissues, resulting in the typical manifestations of the metabolic syndrome. Liver steatosis of different origins constitutes a physiopathological condition where an altered hepatic SEC is observed. In this condition, there is an increased expression of RCB1 and/or higher endocannabinoid levels in different hepatic cells, which may exert an autocrine/paracrine hyperstimulation of RCB1/RCB2. Activation of RCB1 stimulate the expression of several hepatocyte lipogenic factors, thus leading to increased de novo fatty acids synthesis and consequently to an abnormal accumulation of triglycerides. The effect of RCB2 activity on hepatic function is still controversial because, on one side its stimulation has an interesting protective effect on alcoholic liver disease while, on the other, it may enhance the development of hepatic steatosis in experimental models of diet-induced obesity. In this review we discuss the proposed mechanisms by which SEC is involved in the etiology of hepatic steatosis, as well as the therapeutic possibilities involving peripheral RCB1/RCB2 antagonism/agonism, for the treatment of this condition.

Anti-atherosclerosis role of N-oleoylethanolamine in CB2 / 药学学报

To observe a PPAR-alpha agonist effect of N-oleoylethanolamine (OEA) on CB2 (cannabinoid receptor 2), an anti-inflammatory receptor in vascular endothelial cell, healthy HUVECs and TNF-alpha induced HUVECs were used to establish a human vascular endothelial cell inflammatory model. Different doses of OEA (10, 50 and 100 micromol x L(-1)) had been given to HUVECs, cultured at 37 degrees C for 7 h and then collected the total protein and total mRNA. CB2 protein expression was detected by Western blotting and CB2 mRNA expression was assayed by real-time PCR. As the results shown, OEA (10 and 50 micromol x L(-1)) could induce the CB2 protein and mRNA expression, but not 100 micromol x L(-1). To detect if anti-inflammation effect of OEA is partly through CB2, CB2 inhibitor AM630 was used to inhibit HUVEC CB2 expression, then the VCAM-1 expression induced by TNF-alpha was detected, or THP-1 adhere to TNF-alpha induced HUVECs was examined. OEA (50 micromol x L(-1)) could inhibit TNF-alpha induced VCAM-1 expression and THP-1 adhere to HUVECs, these effects could be partly inhibited by a CB2 inhibitor AM630. The anti-inflammation effect of OEA is induced by PPAR-alpha and CB2, suggesting that CB2 signaling could be a target for anti-atherosclerosis, OEA have wide effect in anti-inflammation, it may have better therapeutic potential in anti-inflammation in HUVECs, thus achieving anti-atherosclerosis effect.

Mechanism investigation of platelet apoptosis inhibition by N-Arachidonoylethanolamine / 中华血液学杂志

<p><b>OBJECTIVE</b>To investigate the mechanism of N- Arachidonoylethanolamine (ANA) on inhibiting platelets (PLT) apoptosis under standard blood bank storage conditions.</p><p><b>METHODS</b>Samples taken from collected apheresis PLT by the Amicus instrument were split into three parts. An aliquot of 0.5 μmol/L ANA were added to one part of storage PLT as the ANA group; an aliquot of 0.5 μmol/L ANA and 1 μmol/L SR141716 was added to the another part as the ANA + SR141716 group; and the third part without ANA and SR141716 as the control group. These samples were stored on a flat-bed shaker at (22 ± 2) ⁰C for 7 days. The expression of phosphatidyl serine (PS) positive, phospho (p)-Akt, Akt, p-Bad, Bad, caspase-3, caspase-9, cytochrome C (Cyt-C) and BCL-XL interaction with Bak were detected.</p><p><b>RESULTS</b>The rate of PLT PS positive in ANA group decreased significantly than that in control group[ (8.29 ± 1.44) % vs (14.24 ± 2.47) %, P<0.05]. The release of Cyt-C from mitochondria to cytosol in ANA group decreased significantly compared with control group[ (3.29 ± 1.44) % vs (15.24 ± 3.40) %, P<0.05]. Also the expressions of p-Akt and p-Bad in ANA group increased significantly than those in control group[ (71.33 ± 10.26) % vs (35.00 ± 6.00) %, P<0.05; (39.00 ± 9.64) % vs (10.33 ± 1.53) %, P<0.05, respectively]. Higher amounts of Bak protein were co-precipitated with BCL-XL in ANA group than that in control group (about 2.6 fold, P<0.05). The expressions of cleaved caspase- 9 and caspase- 3 in ANA group decreased significantly than those in control group[ (9.63 ± 1.47) % vs (23.24 ± 2.47) %, P<0.05; (6.30 ± 1.40) % vs (13.20 ± 2.50) %, P<0.05, respectively]. There were no significantly changes between ANA+SR141716 and control groups (P>0.05).</p><p><b>CONCLUSION</b>ANA protected PLTs from apoptosis as a result of inhibiting the release of Cyt-C from mitochondria to cytosol by modifying the expressions of apoptosis-relative proteins.</p>

El dolor: los opioides: los anti-inflamatorios no esteroideos y los canabinoides / Pain: opioids: nonsteroidal antiinflammatory drugs and cannabinoids

Aquí exponemos un modelo que explica por qué, en el sistema nervioso central, los anti-inflamatorios no esteroideos, para ejercer su acción analgésica, deben interactuar con los opioides endógenos y los canabinoides endógenos. La sustancia gris del acueducto de Silvio es una estructura clave del llamado "sistema descendente de control nociceptivo". La activación de este sistema disminuye el flujo de mensajes nociceptivos hacia la corteza cerebral y, por lo tanto, el dolor. En la sustancia gris el ácido araquidónico es el elemento donde los opioides endógenos, los analgésicos opioides y los no-opioides (anti-inflamatorios no esteroideos) convergen para inducir analgesia. Las enzimas degradantes de los endocanabinoides son el punto donde estos y los analgésicos no-opioides convergen para inducir analgesia. Parece ventajoso el hecho de que los analgésicos que se compran libremente en la farmacia pueden aprovechar para su acción los mecanismos endógenos que todos nosotros poseemos

Here we present a model that explains why, in the central nervous system, the nonsteroidal antiinflammatory drugs, in order to induce analgesia, must interact with the endogenous opioids and the endocannabinoids. The periaqueductal gray matter is a key structure in the socalled "descending pain control system". Activations of this system diminishes the flow of nociceptive signals towards the cerebral cortex and, therefore, pain perception. In the periaqueductal gray matter, arachidonic acid is the elements where endogenous opioids analgesics and nonopioid analgesics converge to induce analgasia. The endocannabinoid metabolizing enzyme are the point at which endocannabinoids and nonsteroidal antinflammatory drugs converge to induce analgesia. There seems to be some advantage in that analgesics that can be bought over the counter can use for their action some endogenous mechanisms that we all possess

A aspirina, os opiáceos e a maconha no sistema endógeno de controle da dor / Aspirin, opiates and marijuana in the system of endogenous pain control

Tradução de Diego Molina e revisão do Prof. Dr. Luiz Roberto Giorgetti de Britto. O original em espanhol - "La aspirina, los opioides y la marijuana en el sistema endógeno de control del dolor" - encontra-se à disposição do leitor no Instituto de Estudos Avançados da USP para eventual consulta.